In advanced gastrointestinal tumor patients who were treated with PD‐1 inhibitors, Yue CY et al found that those with high PD‐L1 expression on CTCs had prolonged PFS and higher disease control rate compared with those with low expression.47 This evidence concerns the gene CD274 and digestive system neoplasm.